TY - JOUR
T1 - Sex differences in outcome with bevacizumab therapy
T2 - Analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the eastern cooperative oncology group trial 4599
AU - Brahmer, Julie R.
AU - Dahlberg, Suzanne E.
AU - Gray, Robert J.
AU - Schiller, Joan H.
AU - Perry, Michael C.
AU - Sandler, Alan
AU - Johnson, David H.
N1 - Funding Information:
Supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA16116, CA21076, and CA49957, National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services.
PY - 2011/1
Y1 - 2011/1
N2 - INTRODUCTION: E4599 compared carboplatin and paclitaxel with (PCB) or without (PC) bevacizumab in patients with advanced-stage non-small cell lung cancer. Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab. METHODS: Known prognostic factors and toxicities were compared by sex. Proportional hazards models of survival with multiple factor combinations were used to adjust for treatment effect. RESULTS: The analysis includes 850 patients. The median survival was 8.7 months (PC) versus 11.7 months (PCB) for males (p = 0.001) and 13.1 months (PC) versus 13.3 months (PCB) for females (p = 0.87). Progression-free survival and response rate on the PCB arm were 6.3 months and 29% for males and 6.2 months and 41% for females (p > 0.05). Progression-free survival and response rate on the PC arm were 4.3 months and 16% for males and 5.3 months and 14% for females (p > 0.05). No significant demographic differences were seen between the two arms for males, whereas fewer females on the PCB arm had liver metastasis (PCB 11.7% versus PC 23.2%, p = 0.003). Adverse events with a sex difference on the PCB arm included severe hypertension (males: 4.2%, females: 9.9%, p = 0.02), constipation (males: 1.4%, females: 4.7%, p = 0.05), and abdominal pain (males: 0.9%, females: 5.2%, p = 0.01). In the proportional hazards model adjusting for the other factors, the test for a sex by treatment interaction was not significant (p = 0.09). CONCLUSIONS: Multiple factors may contribute to the apparent sex-specific differences in efficacy of bevacizumab noted in this study.
AB - INTRODUCTION: E4599 compared carboplatin and paclitaxel with (PCB) or without (PC) bevacizumab in patients with advanced-stage non-small cell lung cancer. Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab. METHODS: Known prognostic factors and toxicities were compared by sex. Proportional hazards models of survival with multiple factor combinations were used to adjust for treatment effect. RESULTS: The analysis includes 850 patients. The median survival was 8.7 months (PC) versus 11.7 months (PCB) for males (p = 0.001) and 13.1 months (PC) versus 13.3 months (PCB) for females (p = 0.87). Progression-free survival and response rate on the PCB arm were 6.3 months and 29% for males and 6.2 months and 41% for females (p > 0.05). Progression-free survival and response rate on the PC arm were 4.3 months and 16% for males and 5.3 months and 14% for females (p > 0.05). No significant demographic differences were seen between the two arms for males, whereas fewer females on the PCB arm had liver metastasis (PCB 11.7% versus PC 23.2%, p = 0.003). Adverse events with a sex difference on the PCB arm included severe hypertension (males: 4.2%, females: 9.9%, p = 0.02), constipation (males: 1.4%, females: 4.7%, p = 0.05), and abdominal pain (males: 0.9%, females: 5.2%, p = 0.01). In the proportional hazards model adjusting for the other factors, the test for a sex by treatment interaction was not significant (p = 0.09). CONCLUSIONS: Multiple factors may contribute to the apparent sex-specific differences in efficacy of bevacizumab noted in this study.
KW - Bevacizumab
KW - Non-small cell lung cancer
KW - Sex differences
UR - http://www.scopus.com/inward/record.url?scp=78651107053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651107053&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e3181fa8efd
DO - 10.1097/JTO.0b013e3181fa8efd
M3 - Article
C2 - 21079521
AN - SCOPUS:78651107053
SN - 1556-0864
VL - 6
SP - 103
EP - 108
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 1
ER -